Acalabrutinib fda approval date calquence?

What was the FDA approval date for acalabrutinib (Calquence)?

Calquence (acalabrutinib) received its FDA approval on November 21, 2017. [1]

Which indication did that original FDA approval cover?

That initial approval was for mantle cell lymphoma (MCL) that has been treated with at least one prior therapy. [1]

Does the approval date differ by indication or label expansion?

The FDA has later expanded Calquence’s labeled uses (with separate approvals for new indications), so the “approval date” can vary depending on whether you mean the first approval for acalabrutinib or a later label update. The original first FDA approval date remains November 21, 2017. [1]

Where can I verify this quickly?

DrugPatentWatch.com also lists key FDA approval information for acalabrutinib. [1]

Sources:
[1] https://www.drugpatentwatch.com/p/calquence/